SOTYKTU (deucravacitinib) is a prescription medicine used to treat adults with moderate-to-severe plaque psoriasis who may benefit from taking injections or pills (systemic therapy) or treatment using ultraviolet or UV light (phototherapy). It is not known if SOTYKTU is safe and effective in children under 18 years of age.
HERE'S A LOOK AT HOW IT WORKS
Moderate to severe plaque psoriasis can be really difficult to live with. It can make your skin itchy, scaly, and painful. While people may think it’s only visible on the surface of the skin, psoriasis starts inside your body.
Normally, your immune system works to protect you from infections and illness. Scientists don’t know the exact reason why, but in psoriasis, your immune system becomes overactive. This means parts of your immune system send too many inflammatory signals.
TYK2 is one of the molecules in your immune system that plays a key role in passing on these signals throughout your body. This can lead to inﬂammation, and can cause skin to build up and form plaques.
SOTYKTU is the only pill that selectively targets TYK2.
SOTYKTU is the only FDA-approved once-daily pill that selectively targets and blocks TYK2 signals. It is not currently known how blocking TYK2 signals works to reduce psoriasis symptoms.